Direct answer:The annual reporting requirements of the FDA for the applicable electronic products of radiation emissionses are based on 21 CFR 1002.13: annual reports are submitted by 1 September of each year and cover the 12-month period up to 30 June of the year. As an example of FDA’s FAQ, the report submitted on 1 September 2026 covers the period from 1 July 2025 to 30 June 2026.The nature of the document, the current status and the enterprise recommendations are set out below; Specific products should be judged in the official language.

What is this file, at what stage?

The regulatory document and its status referred to in this paper is based on the original FDA page listing. The report number is not FDA approval of the product; Different product categories, reporting types and import scenarios are verified on the basis of 21 CFR Part 1000.

A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.

Which enterprises and products need attention?

Manufacturers, importers and teams responsible for United States import documents subject to reporting requirements for FDA radiation-launched electronic products.

It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.

Where is the change from what was previously requested?

The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.

The annual reporting requirements of the FDA for the applicable electronic products of radiation emissionses are based on 21 CFR 1002.13: annual reports are submitted by 1 September of each year and cover the 12-month period up to 30 June of the year. FDA’s FAQ exemplifies that the report submitted on 1 September 2026 covered the period 1 July 2025 to 30 June 2026.

Accession Numer is the number used to identify the product report when it is received by the FDA and entered into the report. The FDA clearly states that the receipt of a reply or the acquisition of a number does not represent the approval of the product or the adequacy of the report.

If the product requires an import declaration, the FDA recommends that the report be submitted at least one month before the import in order to receive a return with accession Numer; This number may be required at the time of import, where applicable, in import documents such as FDA 2877. Specific requirements are checked against product categories and declarations.

  1. Determines whether the product falls into the category of radiation-emitting product that requires reporting or annual reporting.
  2. The required records are organized by manufacturer, product type and reporting cycle.
  3. Checks for accession Number, product code and model information already available.
  4. Annual report alerts are set to allow processing time for clearance and submission.
  5. The return number is consistent with import declarations and product information.

Key dates and transitional arrangements

The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.

  • 1 September 2026: Dates listed in the document (as expressed in the original language of the adjacent official).
  • 1 July 2025: Dates listed in the document (as expressed in the original language of the adjacent official).
  • 30 June 2026: Dates listed in the document (as expressed in the original language of the adjacent official).

The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.

How can Chinese companies prepare?

  1. Check whether products fall under the scope of the report, the annual reporting cycle, the September 1 node and the pre-import submission buffer; Maintain Accession Number at FDA request.
  2. Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
  3. If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.

For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.

Exceptions, pending confirmations and common misreading

  • The report number is not FDA approval of the product; Different product categories, reporting types and import scenarios are verified on the basis of 21 CFR Part 1000.
  • When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
  • Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.

Official information and reconciliation records

(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.

Next

Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.